arrow
R

Robin Kate Kelley

university of california
H指数:94
被引数:7.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-line durvalumab and tremelimumab in poor-prognosis unresectable hepatocellular carcinoma: Phase IIIb single-arm SIERRA study

一线度伐利尤单抗和特瑞普利单抗在预后不良的不可切除肝细胞癌中的应用:IIIb期单臂SIERRA研究

2026-10-060
OAAI
Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses

通过全基因组关联研究和整合分析揭示胆管癌及其亚型的遗传景观

2026-02-010
PRE
Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis

IIIb期SIERRA研究早期安全性结果:度伐利尤单抗和特瑞普利单抗作为不可切除肝细胞癌且预后不良患者的一线治疗方案。

2025-12-010
OA
BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update

用于预后预测和治疗建议的BCLC策略: 2025更新

2025-10-270
PRE
Linkage disequilibrium score regression identifies genetic correlations between hepatocellular carcinoma and clinically relevant traits

连锁不平衡评分回归识别肝细胞癌与临床相关性状之间的遗传相关性

2025-09-270
OAAI
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment

《柳叶刀》关于应对全球肝细胞癌负担的委员会报告:从预防到治疗的综合策略

2025-07-280
PRE
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC

HIMALAYA研究五-year总体生存率更新:曲美木单抗联合度伐利尤单抗治疗不可切除性HCC

2025-04-110
OAAI
Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

Tremelimumab (T) 联合 Durvalumab (D) 治疗不可切除性肝细胞癌(uHCC)的III期HIMALAYA研究中,基于基线肝功能的5年总生存期(OS)和总生存期(OS)。

2024-12-011
PRE
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma

精准肿瘤学中耐药性解码模型:胆管癌对FGFR抑制剂的获得性耐药

2024-12-011
OAAI
KEYNOTE-966: 3-year follow-up for pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) vs placebo (pbo) plus gem/cis for patients (pts) with advanced biliary tract cancer (BTC)

KEYNOTE-966: Pembrolizumab(pembro)联合吉西他滨和顺铂(gem/cis)对比安慰剂(pbo)联合吉西他滨和顺铂,用于晚期胆道癌(BTC)患者的3年随访研究。

2024-12-011
PRE
COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC
2024-06-040
OAAI
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

tremelimumab联合durvalumab治疗不可切除肝细胞癌的III期喜马拉雅研究的四年总生存期更新

2024-05-0139
OA
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study

卡博替尼联合阿特珠单抗与索拉非尼治疗晚期肝细胞癌 (COSMIC-312): 一项随机3期研究的最终结果

2024-04-0119
PRE